An unexplained death at a Russian plague research institute has prompted international scrutiny. The incident raises questions about laboratory safety, transparent reporting, and infection prevention preparedness while the cause remains unconfirmed.
|Articles|March 9, 2017
Scientists Reveal Structure of Potential Leishmaniasis Vaccine
Leishmaniasis, caused by the bite of a sand fly carrying a Leishmania parasite, infects around a million people a year around the world. Now, making progress toward a vaccine against the parasitic disease, researchers reporting in PLOS Neglected Tropical Diseases have characterized the structure of a protein from sand flies that can convey immunity to Leishmania.
Advertisement
Scientists are working on a vaccine for Leishmaniasis. Courtesy of Michael Wunderli
Leishmaniasis, caused by the bite of a sand fly carrying a Leishmania parasite, infects around a million people a year around the world. Now, making progress toward a vaccine against the parasitic disease, researchers reporting in PLOS Neglected Tropical Diseases have characterized the structure of a protein from sand flies that can convey immunity to Leishmania.
Previous studies have shown that exposing mice or hamsters to sand fly saliva can protect them against infection by the Leishmania protozoa. Scientists homed in on a protein called SALO (Salivary Anticomplement of Lutzomyia longipalpis) as the key sand fly player in the immune response. The protein is now being pursued as a vaccine candidate for immunizing humans against leishmaniasis.
In the new work, Oluwatoyin Asojo, of the Sabin Vaccine Institute at Baylor College of Medicine, and colleagues put the SALO gene into yeast cells to produce the SALO protein. Then, they studied the recombinant version of SALO, testing its effect on the immune systems of mice and determining its physical structure.
Recombinant SALO, the researchers showed, produced an immune reaction in mice sufficient to convey long-term protection. The SALO protein, they determined, had no appreciable structure similarities to any human protein, and only limited similarities to other insect proteins. Moreover, they were able to pinpoint three parts of the structure that are predicted to interact with human immune cells.
"This work demonstrates that SALO is suitable for further scale-up, manufacturing, and testing as a vaccine candidate against leishmaniasis," the researchers conclude. "The structure of SALO is novel and unique to sand flies with no resemblance to any protein sequence or structure from humans."
Reference: Asojo OA, Kelleher A, Liu Z, Pollet J, Hudspeth E, Rezende WC, et al. (2017) Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis. PLoS Negl Trop Dis 11(3): e0005374. doi:10.1371/journal.pntd.0005374
Advertisement
Related to this article
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.
This week's coverage in Infection Control Today centered on a common thread: the systems, partnerships, and data that let infection prevention teams catch problems before patients are harmed.
UPMC’s genomic surveillance initiative earned national recognition for patient safety. Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, explains how the award could help infection preventionists secure leadership support and sustainable funding for earlier outbreak detection.
Knowing the protocol is only the beginning. In The Clean Bite, Sherrie Busby explores how explaining the why, addressing staff concerns, and creating clear procedures can help dental teams make infection control part of everyday practice.
What might infection prevention rounds miss when visible conditions dominate the conversation? Tommy Davis, PhD, CMIP, a member of ICT's executive advisory board, makes the case for structured observations of clinical workflows, shared accountability, and greater attention to environmental services staff’s insights.
A proposed $27.7 million reduction in AHRQ funding raises questions about support for infection prevention research and implementation. Here is what the September 25 announcement identifies, as well as what remains unknown about specific IPC programs.
Advertisement
Advertisement